AMT receives orphan drug designation from the U.S. Food and Drug Administration Duchenne Muscular Dystrophy gene therapy

28-Sep-2010 - Netherlands

Amsterdam Molecular Therapeutics (AMT) Holding N.V. announced that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency granted AMT-080 orphan designation for the same indication in the European Union.

AMT has shown efficacy in studies of a preclinical model of DMD. These proof of concept studies demonstrated that AMT’s technology resulted in functional dystrophin synthesis in both the heart and skeletal muscles, leading to the prevention of muscular dystrophy. These data are strengthened by a study in which this gene therapy approach was shown to successfully restore dystrophin activity in diseased human muscle cells obtained from biopsies of DMD patients. A Phase I/II clinical trial is scheduled to start by the end of 2012.

AMT has received an Innovation Credit of up to € 4 million from the Dutch government to support the development of AMT’s gene therapy treatment for Duchenne Muscular Dystrophy (DMD). The credit is granted by SenterNovem, an agency of the Dutch Ministry of Economic affairs.

“It is exceptional that we have been able to reveal the promise of this therapy to the FDA in this early stage of the development. We believe our proven adenoassociated viral vector technology used in all our gene therapy products provides a distinct advantage. AMT has successfully conducted three clinical trials with its lead product Glybera that employs this technology, confirming that AAV-based delivery technology is safe and efficacious,” noted Jörn Aldag, CEO of Amsterdam Molecular Therapeutics.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.